TR200101082T2 - Compositions to improve awareness or perception. - Google Patents
Compositions to improve awareness or perception.Info
- Publication number
- TR200101082T2 TR200101082T2 TR2001/01082T TR200101082T TR200101082T2 TR 200101082 T2 TR200101082 T2 TR 200101082T2 TR 2001/01082 T TR2001/01082 T TR 2001/01082T TR 200101082 T TR200101082 T TR 200101082T TR 200101082 T2 TR200101082 T2 TR 200101082T2
- Authority
- TR
- Turkey
- Prior art keywords
- active ingredient
- perception
- alzheimer
- disease
- compositions
- Prior art date
Links
- 230000008447 perception Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Bu bulus, bir tasiyici ve her biri, psikoz veya Alzheimer hastaligi veya iliskili demanslardan müzdarip hastalarda, terapötik açidan yararli bir etki meydana getiren bir miktarda olmak üzere, bir birinci aktif bilesen olarak tipik olmayan bir antipsikotik madde (I) ve ikinci aktif madde olarak bir asetilkolinesteraz inhibitörü (II) ihtiva eden farmasötik bilesimlerle ilgilidir. Sözü edilen yararli etki, Alzheimer hastaligi veya iliskili demanslardan müzdarip hastalarin bilinç islevleri üzerinde sinerjistik bir etki, veya söz konusu hastalarda algilama yeteneginin daha fazla kötülesmesinin önlenmesi, veya aktif maddelerden biri ile baglantili olumsuz etkilerin aktif bilesenlerden digeri tarafindan azaltilmasi seklinde olabilir.This invention is a carrier and a non-typical antipsychotic agent (I) as a first active ingredient (I) and a second active ingredient, each in an amount that produces a therapeutically beneficial effect in patients suffering from psychosis or Alzheimer's disease or related dementias. It relates to pharmaceutical compositions containing acetylcholinesterase inhibitor (II). Said beneficial effect may be a synergistic effect on consciousness functions of patients suffering from Alzheimer's disease or associated dementia, or a reduction in the detrimental ability of perception in such patients, or reduction of negative effects associated with one of the active ingredients by the other active ingredient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454 | 1998-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200101082T2 true TR200101082T2 (en) | 2001-09-21 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/01082T TR200101082T2 (en) | 1998-10-16 | 1999-10-12 | Compositions to improve awareness or perception. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (en) |
| JP (1) | JP2002527469A (en) |
| KR (1) | KR20010072878A (en) |
| CN (1) | CN1367697A (en) |
| AU (1) | AU6472799A (en) |
| BG (1) | BG105302A (en) |
| BR (1) | BR9914419A (en) |
| CA (1) | CA2345767A1 (en) |
| EE (1) | EE200100136A (en) |
| HK (1) | HK1039745A1 (en) |
| HR (1) | HRP20010262A2 (en) |
| HU (1) | HUP0103781A3 (en) |
| ID (1) | ID28441A (en) |
| IL (1) | IL142588A0 (en) |
| NO (1) | NO20011403L (en) |
| PL (1) | PL348107A1 (en) |
| SK (1) | SK4592001A3 (en) |
| TR (1) | TR200101082T2 (en) |
| WO (1) | WO2000023057A2 (en) |
| ZA (1) | ZA200103081B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| BRPI0213564B8 (en) | 2001-10-30 | 2021-05-25 | Novartis Ag | deposit and microparticle formulation comprising iloperidone and poly(d,l-lactide-co-glycolide) polymer, and process for preparing said microparticle |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| EP1776089A2 (en) * | 2003-12-31 | 2007-04-25 | Actavis Group hf | Donepezil formulations |
| CN1922176A (en) * | 2004-12-10 | 2007-02-28 | 艾博特公司 | Condensed bicycle heterocycle substituted quinuclidine derivant |
| JP5379692B2 (en) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (en) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | Thiourea derivatives as glutaminyl cyclase inhibitors |
| MX2007008642A (en) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias. |
| CN102905532A (en) | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | Methods and compositions for improving cognitive function |
| JP6026284B2 (en) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | Inhibitors of glutaminyl cyclase |
| DK2545047T3 (en) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocyclic Inhibitors of Glutaminyl Cyclase (QC, EC 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| HK1215170A1 (en) | 2012-11-14 | 2016-08-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EA034167B8 (en) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Extended release pharmaceutical compositions of levetiracetam |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0515301A3 (en) * | 1991-05-14 | 1993-06-16 | Ernir Snorrason | Improvements in benzodiazepine treatment by cholinesterterase inhibitors |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| ES2299214T3 (en) * | 1997-08-11 | 2008-05-16 | University Of South Florida | USE OF MECAMILAMINE FOR THE TREATMENT OF NEUROPSYCHIQUIATRIC DISORDERS NICOTINE. |
| WO1999052519A2 (en) * | 1998-04-14 | 1999-10-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
-
1999
- 1999-10-12 PL PL99348107A patent/PL348107A1/en unknown
- 1999-10-12 ID IDW20010828A patent/ID28441A/en unknown
- 1999-10-12 CN CN99812184A patent/CN1367697A/en active Pending
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/en unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/en unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/en unknown
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/en not_active IP Right Cessation
- 1999-10-12 HK HK02100158.6A patent/HK1039745A1/en unknown
- 1999-10-12 IL IL14258899A patent/IL142588A0/en unknown
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/en not_active Withdrawn
- 1999-10-12 HR HR20010262A patent/HRP20010262A2/en not_active Application Discontinuation
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/en not_active Withdrawn
- 1999-10-12 EE EEP200100136A patent/EE200100136A/en unknown
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Ceased
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/en unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/en not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002527469A (en) | 2002-08-27 |
| ID28441A (en) | 2001-05-24 |
| AU6472799A (en) | 2000-05-08 |
| SK4592001A3 (en) | 2001-12-03 |
| HK1039745A1 (en) | 2002-05-10 |
| CA2345767A1 (en) | 2000-04-27 |
| HUP0103781A2 (en) | 2002-03-28 |
| ZA200103081B (en) | 2002-07-12 |
| EP1121131A2 (en) | 2001-08-08 |
| WO2000023057A3 (en) | 2000-07-27 |
| CN1367697A (en) | 2002-09-04 |
| KR20010072878A (en) | 2001-07-31 |
| NO20011403D0 (en) | 2001-03-20 |
| NO20011403L (en) | 2001-03-20 |
| HUP0103781A3 (en) | 2003-09-29 |
| WO2000023057A2 (en) | 2000-04-27 |
| BR9914419A (en) | 2001-06-26 |
| BG105302A (en) | 2001-11-30 |
| EE200100136A (en) | 2002-06-17 |
| PL348107A1 (en) | 2002-05-06 |
| HRP20010262A2 (en) | 2002-06-30 |
| IL142588A0 (en) | 2002-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200101082T2 (en) | Compositions to improve awareness or perception. | |
| DE59106756D1 (en) | Novel anti-epileptics. | |
| TR200100172T2 (en) | Biologically strengthened formulations containing eprosartan in oral solid dosage form | |
| ES2178036T3 (en) | CYCLOSPORINE DERIVATIVES, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN YOU. | |
| TR200101895T2 (en) | Treatment of sexual ailments. | |
| ES2153975T3 (en) | DERIVATIVES OF PIRIMIDONA WITH ANTIFUNGIC ACTIVITY. | |
| ATE297204T1 (en) | REMEDIES FOR NEURODEGENERATIVE DISEASES | |
| MX9701946A (en) | Transporting ophthalmic solution. | |
| ATE211384T1 (en) | USE OF ADENOSINE ANTAGONISTS TO PREVENT AND TREAT PANCREATITIS AND ULCERAS | |
| ATE147981T1 (en) | ADMINISTRATION OF LAMOTRIGINE FOR THE TREATMENT OF NEURO-AIDS | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| ATE228360T1 (en) | STABILIZED THYROID HORMONE DRUGS | |
| TR199700878T1 (en) | Pharmacological compositions containing inhibitors of monamine oxidase B. | |
| TR200003736T2 (en) | Prevention of changes due to anxiety states or depression | |
| TR200200449T2 (en) | Active ingredient combination containing clonidine | |
| NZ319138A (en) | Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi | |
| DE60132008D1 (en) | CETHYLMYRISTATE AND CETYLPALMITATE TREATMENT OF ECCEMENTS AND / OR PSORIASIS | |
| TR199700858A2 (en) | Pharmaceutical compositions for the treatment of Alzheimer's disease. | |
| MXPA03000606A (en) | Benzofuran derivatives and their use as antibacterial agents. | |
| YU25001A (en) | Opticaly active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vaskular desease | |
| DK0917460T3 (en) | Cyclosporin formulation | |
| ATE309803T1 (en) | SPHINGOMYELINASE INHIBITORS AS ACTIVE INGREDIENTS WITH ANTIAPOPTOTIC AND ANTISEPTIC EFFECTS | |
| DK0593520T3 (en) | Compounds containing steroids content and their use in the treatment of glaucoma | |
| LT96094A (en) | The active ingredient of pharmaceutical composition for treating constipation | |
| FR2710844B1 (en) | Composition for the treatment or prevention of herpes. |